Jab duniya GLP-1 weight loss drugs ke baare mein bat kar rahi hai, Divi’s Laboratories quietly un drugs ke ingredients banane ki preparation kar rahi hai. Ye ek genuinely important distinction hai jo Divi’s Labs ki long term story ko interesting banata hai.
DIVISLAB Share Price Target 2026 To 2030
| Year | Target Price (Rs.) Approx |
|---|---|
| 2026 | 6,500 – 8,500 |
| 2027 | 8,000 – 11,000 |
| 2028 | 10,000 – 14,500 |
| 2029 | 12,500 – 18,500 |
| 2030 | 15,500 – 24,000 |
Ye targets maine current price Rs 7,372, FY26 results, analysts ka 22% revenue CAGR FY26-28E estimate, GLP-1 peptide opportunity, Kakinada Unit 3 ramping up, Rs 1,500 crore capex aur Peptide Centre of Excellence launch ko dekhte hue estimate kiye hain. Ye guaranteed returns nahi hain. Raw material cost inflation, US FDA issues ya GLP-1 contract ramp-up delay se targets affect ho sakte hain. Live price ke liye NSE India aur detailed financials ke liye Screener.in dekhna better rahega.
DIVISLAB Share Price Target 2026
2026 ke liye Rs 6,500-8,500 ka range estimate karta hu. Analyst consensus 12-month target Rs 7,000-7,500 range mein tha, aur long term outlook Rs 9,000-12,000 tha. Stock abhi Rs 7,372 par hai jo 52-week high Rs 7,438.50 ke Rs 66 hi neeche hai. Q1 FY27 results August 2026 mein expected hain jo FY27 guidance ka pehla real test honge. Double-digit revenue growth target for FY27 management ne confirm kiya hai jo 2026 mein upper range achieve karne ka catalyst hoga.
ALSO READ- Kalyan Jewellers Share Price Target 2026 To 2030
DIVISLAB Share Price Target 2027
2027 ke liye Rs 8,000-11,000 ka range realistic lagta hai. Brokerages 22% revenue CAGR FY26-28E estimate kar rahi hain commercial CDMO contracts ki wajah se. GLP-1 ingredient contract volumes jo abhi ramp up ho rahe hain 2027 tak meaningful revenue contribution denge. Analysts FY26-28 revenue/EBITDA/EPS CAGR 15%/16%/16% estimate kar rahe hain. Peptide Centre of Excellence jo FY26 mein inaugurate hua 2027 tak full capacity par hoga.
ALSO READ-TMB Share Price Target 2026 To 2030
DIVISLAB Share Price Target 2028
2028 ke liye Rs 10,000-14,500 ka range reasonable lagta hai. Tab tak Divi’s global pharma supply chain diversification trend ki ek central beneficiary ban chuki hogi. China plus one strategy ke under innovator pharma companies India ko preferred API sourcing destination bana rahi hain. Contrast media opportunities aur generic players ko drugs losing patent protection ke liye supplies bhi 2028 tak peak volumes par honge. Kakinada Unit 3 ka full integration aur backward integration benefits bhi tab tak clearly visible honge.
ALSO READ- BLISSGVS Share Price Target 2026 To 2030
DIVISLAB Share Price Target 2029
2029 ke liye Rs 12,500-18,500 ka range dekhta hu. GLP-1 weight loss drugs ki global demand 2029 tak massive scale par hogi aur Divi’s ka peptide manufacturing capability ek direct moat ban chuki hogi. India CDMO space mein Divi’s ki positioning global pharmaceutical companies ke saath long term partnerships ke through solidify ho chuki hogi. Nutraceutical segment bhi tab tak Rs 2,000+ crore annual revenue contributor ban chuka hoga.
ALSO READ-Vedanta Power Share Price Target 2026 To 2030
DIVISLAB Share Price Target 2030
2030 tak Rs 15,500-24,000 ka range estimate karta hu. Ye ambitious lagta hai lekin analysts ka long term outlook already Rs 9,000-12,000 tha March 2026 mein jab stock Rs 6,200 par tha – ye trajectory lagbhag Rs 15,000-24,000 range mein naturally extend hoti hai. Revenue Rs 25,000-30,000 crore tak pahunch sakta hai 2030 mein agar CDMO aur GLP-1 segments successfully scale hue. Lekin ye execution-dependent hai.
ALSO READ-IFCI Limited Share Price Target 2026 To 2030
Stock Market me invest karne se pehle calculate karna zaroori hai
“Brokerage, SIP, CAGR, CAGR Returns, Position Size, Risk-Reward, STT, LTCG, Options, Profit & Loss aur 20+ powerful stock market calculators ka use karein”
Visit the Link – Calculate Now
DIVISLAB Future Growth Plans
FY26 mein Rs 1,500 crore se zyada ka capex hua manufacturing network expand karne, capacity create karne aur technology upgrade karne ke liye.Peptide Centre of Excellence launch hua jo complex peptide synthesis mein capabilities boost karega – ye directly GLP-1 opportunity ko address karta hai.
Kakinada Unit 3 facility jo January 2025 mein operational hua, backward integration ka central hub ban gaya hai FY26 mein six blocks operational aur do aur construction under hain.Nutraceutical revenue FY26 mein Rs 946 crore raha jo pichle saal ke Rs 781 crore se meaningfully badha hai.
Long term manufacturing aur supply agreement ek global pharma company ke saath Rs 650-750 crore capex ke saath sign ki hai advanced intermediates ke liye. India ke pharma export market ke baare mein aur jaankari ke liye Pharmaceuticals Export Promotion Council ki website helpful rahegi.
Latest News Affecting DIVISLAB Share Price
Q4 FY26 mein consolidated PAT Rs 751 crore yaani 13% YoY growth aur revenue Rs 2,831 crore yaani 10% YoY growth raha. Rs 30 per share final dividend announce hua FY26 ke liye record date July 24, 2026.
FY26 full year net profit Rs 2,568 crore yaani 17% YoY growth aur revenue Rs 10,560 crore yaani 12.82% growth raha.Board meeting AGM August 10, 2026 ko scheduled hai. Q1 FY27 results ke liye board meeting intimation bhi announce ho chuki hai.
Q4 ke baad stock 3% slip hua margin worries ki wajah se EBITDA margin 100 bps Q-o-Q aur Y-o-Y lower rahi raw material cost inflation ki wajah se, lekin brokerages CDMO aur GLP-1 opportunities par positive rahe. July 27 ko stock Rs 7,372 par hai.
Company Overview of Divi’s Laboratories Limited
Divi’s Laboratories leading pharmaceutical company hai jo Active Pharmaceutical Ingredients yaani APIs aur nutraceuticals manufacturing mein specialist hai. Ye globally top 3 API manufacturers mein se ek hai aur 100 se zyada countries mein export karta hai. Company headquartered Hyderabad mein hai aur March 2003 mein listed hui thi.
Company do major manufacturing units operate karti hai Andhra Pradesh mein aur international locations Basel Switzerland aur Florham Park New Jersey mein hain. Kakinada District Andhra Pradesh mein Unit 3 April 2023 mein setup ki gayi thi.
Chairperson Ramesh B V Nimmagadda hain. 36th AGM August 10, 2026 ko scheduled hai. Company ke baare mein aur jaankari ke liye Divi’s Laboratories Official Website dekh sakte hain.
DIVISLAB Shareholding Pattern
| Category | Holding (%) – June 2026 |
|---|---|
| Promoters | 51-52% |
| Mutual Funds | 13.87% |
| FIIs | 20-22% |
| Public / Retail | 14-16% |
Mutual Fund shareholding 13.87% hai as of July 21, 2026. Promoter holding approximately 51-52% stable hai. FII holding strong hai jo global institutional confidence dikhata hai. Latest pattern ke liye BSE India check kar sakte hain.
DIVISLAB Dividend History
FY26 ke liye Rs 30 per share final dividend announce hua hai jo face value Rs 2 ka 1500% hai. Record date July 24, 2026. Company consistent dividend paying track record rakhti hai. Rs 30 dividend yield modest hai Rs 7,372 ke stock price par but amount substantial hai.
DIVISLAB Bonus Share and Split History
Divi’s Labs ne historically stock splits kiye hain – face value Rs 10 se Rs 2 kar diya gaya tha. Recent years mein koi major bonus issue nahi aaya hai. Company primarily dividends pe focus karti hai shareholders return ke liye.
DIVISLAB Competitors in India
| Competitor | Type |
|---|---|
| Sun Pharmaceutical | Large Listed Player |
| Dr. Reddy’s Laboratories | Large Listed Player |
| Aurobindo Pharma | Large Listed Player |
| Laurus Labs | Listed CDMO Player |
| Syngene International | Listed CDMO Player |
DIVISLAB – Strengths
FY26 mein revenue Rs 10,560 crore yaani 12.82% growth aur profit Rs 2,568 crore yaani 17% growth. 22% revenue CAGR FY26-28E estimate analysts kar rahe hain commercial CDMO contracts ki wajah se. Company global supply diversification trend ki key beneficiary hai.
Peptide Centre of Excellence aur GLP-1 ingredient opportunity ek massive long term growth driver hai – GLP-1 weight loss drugs globally trillion dollar opportunity ban rahi hai.
Debt-free balance sheet aur strong cash generation ek structural strength hai. 100 countries mein diversified export base ek natural hedge hai. US FDA inspection successfully pass karna quality standards ka proof hai.
DIVISLAB – Weaknesses
Q4 mein EBITDA margin 100 bps neeche aayi raw material cost pressures – crude oil aur ammonia linked inflation – ki wajah se jo ongoing concern hai.
Freight aur raw material cost pressures near term mein persist karne expected hain.
PE 75x abhi premium valuation hai jo kisi bhi earnings miss par sharp correction risk create karta hai. GLP-1 contract ramp-up timeline uncertain hai. Company ne management commentary mein revenue guidance specific nahi di hai jo transparency pe sawaal uthata hai.
Risks Before Investing in DIVISLAB Stock
Raw material cost inflation crude oil aur ammonia prices directly margins ko impact karti hai aur ye uncontrollable external factor hai.Divi’s Labs ne ek draft tax assessment order receive kiya tha Rs 570.51 crore additions proposing FY23 ke liye. Ye regulatory risk monitor karna zaroori hai.
GLP-1 opportunity bahut exciting hai lekin contract ramp-up timeline uncertain hai – delay hone par market expectations disappoint ho sakti hain. Elevated 75x PE par koi bhi negative surprise sharp correction trigger kar sakta hai. FII holding high hone se global risk-off mein selling pressure possible hai. US FDA ka China API manufacturers par lenient stance hone par competitive dynamics change ho sakte hain. Government tenders ke updates ke liye SEBI Investor Education Portal visit kar sakte hain.
Is DIVISLAB Share Good to Buy?
Rs 7,372 par stock 52-week high ke bilkul paas hai aur 75x PE premium valuation hai. Ye koi “cheap” stock nahi hai. Lekin quality companies kabhi sasti nahi milti. GLP-1 opportunity jo aage aa rahi hai, CDMO contracts, clean balance sheet aur double-digit FY27 guidance – ye sab factors ek compelling case banate hain long term investors ke liye. Rs 1,500 crore capex jo FY26 mein hua uska full revenue benefit FY27-28 mein aayega. Main ise portfolio mein 5-8% allocation ke saath appropriate manta hu agar 3+ saal ki horizon ho.
Is DIVISLAB Share Good for Long-Term Investment?
Genuinely haan. India CDMO sector ka future bright hai aur Divi’s ek established global player hai. Long term analyst outlook Rs 9,000-12,000 tha jab stock Rs 6,200 par tha ab stock Rs 7,372 par hai to long term trajectory aur higher hai.
Is DIVISLAB Share Good for Short-Term Investment?
Short term mein stock 52-week high ke bilkul paas hai aur near term mein consolidation ya minor correction possible hai. Q1 FY27 results August 2026 mein key catalyst honge. Short term traders ke liye better entry Rs 6,800-7,000 zone par milegi agar correction aaya.
Is DIVISLAB Better for Dividend Investors or Growth Investors?
Rs 30 per share dividend FY26 mein milta hai lekin yield modest hai high stock price par. Primarily growth stock hai ye. Growth investors ke liye CDMO aur GLP-1 opportunity ek multi-year compounding story hai.
DIVISLAB Share Price Target Based on Technical Analysis
July 27, 2026 ki technical picture yeh hai:
| Level Type | Price Zone (Rs.) |
|---|---|
| 52-Week Low | 5,636.50 |
| 200 DMA | 6,427.10 |
| 50 DMA | 6,778.52 |
| Current Price (July 27) | 7,372 |
| 52-Week High | 7,438.50 |
| Immediate Resistance | 7,438 – 7,500 |
| Strong Resistance | 7,800 – 8,000 |
DIVISLAB Share Price Target Based on Fundamental Analysis
FY26 full year revenue Rs 10,560 crore yaani 12.82% growth aur net profit Rs 2,568 crore yaani 17% growth. Q4 FY26 PAT Rs 751 crore yaani 13% YoY growth aur revenue Rs 2,831 crore yaani 10% growth.
EPS FY26 Rs 96.75 hai. PE 75.34x aur PB 11.54x hai. Market cap Rs 1,93,479 crore hai.Material consumption 38.8% of sales – FY25 ke 39.8% se improved.15-16% EPS CAGR FY26-28E analyst estimates.
Expert Opinion on DIVISLAB Share
Ye stock Indian pharma space mein ek true quality compounder hai. Debt-free balance sheet, consistent profit growth, globally respected API manufacturing capabilities aur ab GLP-1 peptide opportunity – ye sab factors Divi’s Labs ko genuinely special banate hain. Analysts 22% revenue CAGR expect kar rahe hain FY26-28E jo ek large cap pharma company ke liye exceptional hai. Concern ye hai ki 75x PE par valuation already quite stretched hai aur raw material inflation margin pe pressure create kar rahi hai. Main ise portfolio mein 5-7% allocation ke saath hold karuga aur Q1 FY27 results mein double-digit growth confirm hone par comfortable rahunga. Rs 6,800-7,000 correction zone par better entry opportunity milegi aggressive investors ke liye.
Conclusion
Divi’s Laboratories ek aisi company hai jisme silently excellent operate karne ka track record hai. FY26 mein Rs 2,568 crore profit, 17% growth, Rs 1,500 crore capex, Peptide Centre of Excellence, Kakinada Unit 3 ramping up aur Rs 30 dividend – ye numbers ek genuinely well-run pharmaceutical company ki kahani hain. GLP-1 aur CDMO opportunity jo ahead hai ek multi-year growth catalyst hai. Lekin premium valuation, raw material cost pressures aur tax notice ek balanced view ke liye zaroori hain. Long term patient investors ke liye ye ek quality large-cap pharma compounding bet hai. Invest karne se pehle apni research zaroor karo aur SEBI registered advisor se salah lo, iske liye SEBI Investor Education Portal visit kar sakte hain.
Frequently Asked Questions
Q1. DIVISLAB share price target 2026 kya hai?
Rs 6,500-8,500 ka range realistic hai 2026 ke liye. Abhi stock Rs 7,372 par hai aur 52-week high Rs 7,438 ke bilkul paas hai.
Q2. DIVISLAB share price target 2027 kya hai?
2027 ke liye Rs 8,000-11,000 ka range estimate hai agar 22% revenue CAGR momentum continue raha aur GLP-1 contracts ramp up hue.
Q3. DIVISLAB share price target 2028 kya hai?
2028 ke liye Rs 10,000-14,500 ka range reasonable hai jab Kakinada Unit 3 full integration aur CDMO contracts peak volumes par honge.
Q4. DIVISLAB share price target 2029 kya hai?
2029 ke liye Rs 12,500-18,500 ka range tabhi achieve hoga jab GLP-1 peptide manufacturing globally significant scale par ho.
Q5. DIVISLAB share price target 2030 kya hai?
2030 ke liye Rs 15,500-24,000 ka range estimate hai agar CDMO aur nutraceuticals dono segments successfully scale hue aur revenue Rs 25,000+ crore zone mein pahuncha.
Q6. Divi’s Laboratories FY26 results kaisa raha?
FY26 mein revenue Rs 10,560 crore yaani 12.82% growth aur net profit Rs 2,568 crore yaani 17% growth. Q4 mein highest-ever quarterly revenue Rs 2,831 crore raha.
Q7. Divi’s Labs dividend kitna deta hai?
FY26 ke liye Rs 30 per share final dividend announce hua hai. Record date July 24, 2026 thi.
Disclaimer
Main SEBI registered advisor nahi hu. Ye article sirf educational purpose ke liye likha gaya hai. Stock market mein invest karne se pehle apni khud ki research zaroor karein aur agar zaroorat lage to qualified financial advisor se salah lein. Kisi bhi profit ya loss ki zimmedari meri nahi hogi.